Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...

(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...

Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese ...

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...

Merck (MRK) stock gains as company enters a global licensing deal with Hansoh Pharma to develop an oral obesity drug. Read ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...

The company also intends to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction. Under the terms of the deal, Hansoh Pharma will receive an ...

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral ...

Merck & Co. Inc. and Hansoh Pharmaceutical Group Co. Ltd. have entered into an exclusive global license agreement for ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...